Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)
February 09 2021 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ¨
Filed by a Party other than the Registrant x
Check the appropriate box:
¨ Preliminary
Proxy Statement
¨ Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive
Proxy Statement
¨ Definitive
Additional Materials
x Soliciting
Material under §240.14a-12
Aptevo Therapeutics Inc.
(Name of Registrant as Specified In Its
Charter)
Tang Capital
Partners, LP
Tang Capital
Management, LLC
Kevin
Tang
Thomas
Wei
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x No fee
required.
¨ Fee computed
on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
¨Fee paid previously
with preliminary materials.
¨Check box if
any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing.
(1) Amount
Previously Paid:_____________________________________________________________________________
(2) Form,
Schedule or Registration Statement No.:_____________________________________________________________
(3) Filing
Party: ______________________________________________________________________________________
(4) Date
Filed: _______________________________________________________________________________________
Explanatory Note:
On February 9, 2021, Tang Capital Partners, LP, Tang Capital
Management, LLC and Kevin Tang (the “Reporting Persons”) filed Amendment No. 2 to their Schedule 13D
relating to Aptevo Therapeutics, Inc. (the “Company”), which included a letter to the board of directors
of the Company, a copy of which is attached as Exhibit 99.1 and incorporated herein by reference.
The Reporting Persons and Thomas Wei may be deemed
to be a participant in the solicitation of proxies with respect to the Company’s 2021 Annual Meeting of Stockholders. A description
of such persons’ interests, by security holdings or otherwise, is contained in Amendment No. 2 to Schedule 13D that the Reporting
Persons have filed with the Securities and Exchange Commission (“SEC”). The participants strongly advise all stockholders
of the Company to read any definitive proxy statements and other proxy materials as they become available, as they will contain
important information. Such proxy materials will be available at no charge on the SEC’s website at www.sec.gov.
2
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jul 2023 to Jul 2024